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Abstract
Background: Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicated
malaria, but there is widespread resistance. At the time of this study, artemether-lumefantrine (AL)
and chlorproguanil-dapsone (CPD), both multi-dose regimes, were considered possible
alternatives to SP in Malawi. The aim of this study was to investigate the impact of poor adherence
on the effectiveness of AL and CPD.
Methods: Children ≥12 months and adults with uncomplicated malaria were randomized to
receive AL, CPD or SP. Adherence was measured using a questionnaire and electronic monitoring
devices, MEMS™, pill bottles that recorded the date and time of opening. Day-7 plasma dapsone
or lumefantrine concentrations were measured to examine their relationship with adherence and
clinical response.
Results: 841 patients were recruited. The day-28 adequate clinical and parasitological response
(ACPR) rates, using intention to treat analysis (missing data treated as failure), were AL 85.2%, CPD
63.7% and SP 50%. ACPR rates for AL were higher than CPD or SP on days 28 and 42 (p ≤ 0.002
for all comparisons). CPD was more effective than SP on day-28 (p = 0.01), but not day-42.
Very high adherence was reported using the questionnaire, 100% for AL treated patients and 99.2%
for the CPD group. Only three CPD participants admitted missing any doses. 164/181 (90.6%) of
CPD treated patients took all their doses out of the MEMS™ container and they were more likely
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0.024. Only 7/87 (8%) AL treated patients did not take all of their doses out of their MEMS™
container and none had treatment failure.
Median day-7 dapsone concentrations were higher in CPD treated patients with ACPR than in
treatment failures, p = 0.012. There were no differences in day-7 dapsone or lumefantrine
concentrations between those who took all their doses from the MEMS™ container and those
who did not. A day-7 lumefantrine concentration reported to be predictive of AL treatment failure
in Thailand was not useful in this population; only one of 16 participants with a concentration below
this threshold (175 ng/ml) had treatment failure.
Conclusion: This study provides reassurance of the effectiveness of AL, even with unsupervised
dosing, as it is rolled out across sub-Saharan Africa. Self-reported adherence appears to be an
unreliable measure of adherence in this population.
Background
In 2007, Malawi switched its first line therapy for uncom-
plicated malaria from sulphadoxine-pyrimethamine (SP)
to artemether-lumefantrine(AL, Coartem™), a fixed-ratio
combination of artemether (AM) with lumefantrine (LU).
The need to take AL twice daily for three successive days
means there is a larger potential for poor adherence with
AL compared to the single dose regimen of SP.
As part of efforts to optimize the operational use of AL, it
is important to assess the effect of poor adherence to
(compliance with) this regime on clinical outcome. This
paper describes a large single centre open label rand-
omized clinical trial to investigate the effect of adherence
upon the effectiveness of AL and chlorproguanil-dapsone
(CPD, Lapdap™) in comparison to SP in a 'real-life' setting
in adults and children with uncomplicated malaria. The
study was initially designed to focus primarily on CPD, an
anti-folate combination, previously shown to be effective
in Africa in areas with high SP resistance [1]. Subsequent
to the completion of the study, CPD was withdrawn by
the manufacturers owing to an unacceptably high risk of
haemolysis in patients with glucose-6-phosphate dehy-
drogenase (G6PD) deficiency [2]. Two different methods
were used to assess adherence, and the relationship
between adherence, day-7 plasma drug concentrations
and clinical responses to AL and CPD was examined.
Methods
Participants and study site
The study took place at Zingwangwa health centre, in the
city of Blantyre, Malawi, where malaria transmission is
perennial, peaking during December to April. Between
May 2004 and April 2006, adults and children presenting
with an illness suggesting falciparum malaria were
screened for malaria parasitaemia by a finger-prick thick
blood film. Patients willing to enter the trial were addi-
tionally screened for eligibility by a questionnaire and
capillary blood sample to check their haemoglobin con-
centration [Hb]. Women ≥12 years had a urine pregnancy
test. Those with a positive blood film were eligible for
enrolment in the study if they fulfilled the following crite-
ria: i) age ≥6 months, ii) weight ≥10 kg, iii) P. falciparum
monoinfection on the blood slide, iv) Hb ≥7 g/dl, and v)
no features suggesting severe malaria or a concomitant ill-
ness. Pregnant or breastfeeding women, women with a
positive pregnancy test and patients with known G6PD
deficiency or allergies to sulphonamide or dapsone were
excluded. Written informed consent was required from
the participant, or from the parent or guardian in the case
of children. Approval was obtained from the research eth-
ics committees of the College of Medicine, University of
Malawi and Liverpool School of Tropical Medicine. A data
and safety monitoring board was appointed. The study
was registered with the Clinical Trials register, ISRCTN
12285821.
Randomization and treatment
Patients meeting inclusion criteria were recruited and ran-
domized to AL, CPD or SP on a 1:2:1 basis. Randomiza-
tion was performed in blocks of 20 using an off-site
computer-generated code. Sealed sequentially numbered
envelopes designating treatment group were opened for
each participant following entry to the trial.
CPD was dosed by height; paediatric and adult tablet for-
mulations were available. A total of three doses of CPD
were prescribed, one daily for three days. AL was dosed by
weight and six doses were prescribed; on recruitment and
after 8, 24, 36, 48 and 60 hours. The single SP dose was
based upon age. The dosing schedules are shown in
Table 1.
The first dose of medication was given at the clinic and
further doses of CPD and AL were taken at home. Verbal
instructions on how to take the remaining doses were
given with advice to take AL with food or milk. A three-
day supply of paracetamol (10 mg/kg) was given to takePage 2 of 11
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other anti-malarial drugs. Participants were observed for
one hour to ensure that the medication was not vomited:
if vomiting occurred within the first hour, the dose was
repeated. Vomiting of the repeated first-dose resulted in
removal from the trial, treatment with parenteral quinine
and transfer to hospital for assessment.
Classification of outcomes
Formal follow up took place on days 7, 14 and 28 but par-
ticipants could present to the clinic on any other day if
unwell. In the second half of the study, follow up was
extended to day-42 to detect treatment failures occurring
after 28 days. Patients who did not attend for follow up
were visited at home by study personnel (subject to con-
sent) to ensure their safety. At each follow up visit, symp-
tom histories were taken, Hb was checked and a malaria
blood slide examined. In addition, on day-7, a venous
blood sample was collected for pharmacokinetic analysis
(see below). Clinical outcome was assessed using modi-
fied World Health Organization (WHO) criteria [3]. Mod-
ification was necessary owing to the lack of scheduled
follow up on days 2 and 3. Participants were withdrawn if
they failed to attend for follow up or withdrew consent.
Measurement of adherence
Adherence with the SP regimen was assured by direct
observation of the single dose therapy. Adherence with AL
and CPD was measured in two ways:
1. Use of simple drug dosing questionnaires on day-7;
participants or guardians were asked how many tablets
had been taken and when.
2. Use of MEMS™ (Aardex Ltd, Switzerland) capped pill
bottles which recorded electronically the date and time
when the medication bottle was opened. Adherence was
estimated by comparing the MEMS™ number of openings
with the prescribed dosing regime. MEMS™ were used in a
sub-group of patients according to availability at the time
of recruitment. The MEMS™ data were interpreted as fol-
lows; for CPD, participants who opened their pill bottle
one time or more on each of the two consecutive days
after recruitment were assumed to have taken all their pre-
scribed doses of medication. Those who failed to open
their pill bottles on the two consecutive days after recruit-
ment were assumed to have missed some doses. For AL, if
the MEMS™ recorded at least one opening of the bottle on
the day of recruitment and at least two more on each of
the next two days, it was assumed that all the doses were
taken.
Laboratory methods
Hemocue® Hb estimates and malaria slides were per-
formed from capillary blood sample at each follow up
visit. Blood slides were stained with Field's stain and par-
asite densities estimated from thick films by counting the
number of parasites per 200 white blood cells assuming a
total count of 8,000/μl. The concentrations of dapsone
(DDS) and lumefantrine (LU) were measured from
venous blood collected on day-7 to determine whether
they were associated with treatment compliance or out-
come. The blood was spun at 2,000 g for 10 minutes in a
refrigerated centrifuged and the plasma removed and
stored at -80°C for the pharmacokinetic analyses.
Dapsone (DDS) was quantified from 0.5 ml of plasma
using HPLC-UV (high performance liquid chromatogra-
phy  ultra-violet) detection using a method developed and
validated in Liverpool (SA Ward, unpublished). Chroma-
tographic separations were carried out using Surveyor
HPLC system (Thermo Fisher Scientific). Internal stand-
ard (pyrimethamine, 500 ng) was added to the plasma
samples along with 0.5 ml sodium hydroxide (0.1 M). The
samples were then vortexed for 10 seconds followed by
the addition of 5 ml dichloromethane and again vortexed
for a further 20 seconds. The samples were then centri-
fuged at 1,600 g for 10 minutes after which the organic
(bottom) layer was transferred to a clean tube. A further 5
ml of dichloromethane was added to the aqueous layer,
vortexed for 20 seconds and centrifuged again at 1,600 g
for 10 minutes with the organic layer collected once more.
Table 1: Dosing schedules for chlorproguanil-dapsone (CPD), artemether-lumefantrine (AL) and sulphadoxine-pyrimethamine (SP)
CPD Paediatric Tablets1 CPD Adult Tablets2 AL3 SP4
One dose, once daily for 3 
days
One dose, once daily for 3 
days
One dose, twice daily for 3 
days
Single dose
Height
(cm)
No. of Tablets per 
dose
Height
(cm)
No. of Tablets per 
dose
Weight
(kg)
No. of Tablets per 
dose
Age (years) No. of Tablets per 
dose
50  64 0.5 115  134 0.5 10  14 1 0.5  <2 0.5
65  84 1 135  164 1 15  24 2 2  8 1
85  104 1.5 ≥ 165 1.5 25  34 3 9  14 2
105  114 2 ≥ 35 4 ≥ 15 3
1Paediatric CPD tablets contained 15 mg of CPG and 18.75 mg of DDS.
2Adult CPD tablets contained 80 mg of CPG and 100 mg of DDS.
3AL tablet contained 20 mg of AM and 120 mg of LU.
4SP tablets contained 500 mg of sulphadoxine and 25 mg of pyrimethamine.Page 3 of 11
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under a steady stream of nitrogen at 30°C. Samples were
reconstituted in 100 μl of mobile phase of which 50 μl
was injected onto column.
Chromatographic separation was achieved using a Phe-
nomenex Synergi 4 μ MAX RP C12 (150 cm × 4.6 mm, 4
μm particle size) column, fitted with a LiChrosphere®
100Rp-18, 5 μ guard column. The mobile phase com-
prised of acetonitrile: triethylamine (0.1% adjusted to pH
3 with ortho-phosphoric acid): methanol (7:70:23 v/v),
flowing at 1 ml/min. Column and tray temperature con-
trol was set at room temperature. The UV detector was set
at 254 nm. Data was captured and processed using Xcali-
bur 1.4 software (Thermo Fisher Scientific). The lower
limit of quantification (LLOQ) of the dapsone assay was
100 ng/ml and the calibration curve was linear in the
range 02500 ng/ml.
Lumefantrine was quantified from 0.25 ml of plasma
using HPLC-UV detection following a previously
described method [4]. The LLOQ of the LU assay was
0.025 ng/ml and the calibration curve was linear in the
range 020 μg/ml.
Statistical methods
The primary aim of the study was to investigate the effect
of incomplete adherence on the effectiveness of AL and
CPD. Effectiveness was assessed by comparing the day-28
"adequate clinical and parasitological response" (ACPR)
rates. The ACPR rates were not corrected using the
polymerase chain reaction (PCR) to distinguish recurrent
parasitaemias due to reinfections and recrudescence (true
treatment failures). Secondary aims were to compare the
effectiveness of AL, CPD and SP on days 28 and 42, to
compare the different methods for measuring adherence,
to investigate the associations between day-7 drug con-
centrations and adherence and treatment outcome and to
compare serious adverse events (SAEs) and Hb changes
after the three treatments.
An approximate sample size of 1,000 participants was cal-
culated, with 500 participants in the CPD group and 250
in the SP and AL groups. Assuming 50% of the partici-
pants were fully adherent, this sample size would detect a
difference between a cure rate of 97% in the CPD arm and
90% in the SP arm with 95% confidence and a power of
80%. Because the initial focus of the study was on CPD,
we planned to recruit twice as many children into that
treatment group than the SP or AL groups. Data were dou-
ble entered and validated prior to the analyses.
Data analysis was performed using Stata 8: the primary
analysis was on an intention to treat (ITT) basis. Binomial
regression was used to obtain risk differences between
treatments and 95% confidence intervals. Fisher's exact p-
values were reported. Tests of significance were performed
using the 0.05 level to infer significance for the planned
analyses. For pair wise comparisons between combina-
tion therapies, we adjusted the significance level to 0.017
(i.e. 0.05/3) using Bonferroni's approach.
Results
Recruitment and participant flow
841 of the 7,536 patients screened met the inclusion crite-
ria and were enrolled. Common reasons for non-recruit-
ment included negative blood slides (n = 6150), Hb <7 g/
dl (n = 189) and the child weighing <10 kg (n = 63). Base-
line characteristics of the recruited patients are shown in
Table 2. 99 (11.8%) patients had been withdrawn from
the study by day-14 and 136 (16.2%) by day-28. Recruit-
ment was extended to 42 days for the last 330 patients
enrolled; 20% of these were withdrawn by day-42
(Figure 1).
Treatment effectiveness
The results of the day-28 and day-42 ITT analyses with
missing outcomes treated both as failures and successes
and the per protocol (PP) analyses are shown in Tables 3
and 4 respectively. In all analyses, the ACPR rates with AL
were significantly higher than the rates in either of the
other groups on days 28 and 42 (p ≤ 0.002 for all compar-
isons). The ACPR rates using CPD were significantly
higher than SP on day-28 but not on day-42.
Haemoglobin changes
Table 5 shows the mean changes in Hb after treatment
with CPD and AL compared to the changes in the SP treat-
ment group on days 7, 14 and 28. No differences in mean
Hb level were observed after treatment with CPD or SP.
Hb initially fell in both groups below the recruitment
level by day-7 but recovered by day-28 to levels above
those on day 0. After treatment with AL, the Hb rose by
day-14 and 28; this rise was significantly greater than the
change after SP.
Safety and tolerability
There were 11 serious adverse events (SAEs) in the study,
including one death, with eight SAEs in the CPD group
and three in the SP treatment group. SAE rates are similar
as 422 patients were recruited to the CPD group and 210
to the SP group. SAEs were defined as any occurrence
resulting in death or admission to hospital for partici-
pants under follow up in the study. The three-year old girl
who died had a recruitment parasite count of 129,000 per
μl, Hb 11.7 g/dl and packed cell volume (PCV) 34%. She
received her first dose of CPD in the clinic. The following
day, she had a convulsion and further fevers and on
admission to hospital was found to a positive malaria
blood slide, PCV 30% and normal blood glucose concen-Page 4 of 11
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ramphenicol and penicillin. Convulsions continued
despite treatment with lorazepam and she died two days
after her admission to hospital with presumed cerebral
malaria.
SAEs in the seven remaining CPD treated patients
included two patients (aged 8 and 20 years) who devel-
oped vomiting and abdominal pain and two adults
admitted with fever one week after recruitment and found
to have Salmonella typhimurium bacteraemia (one was con-
firmed HIV positive, the other was not tested). One
patient developed features of severe malaria (convulsions
and fever with a positive blood slide) 20 days after treat-
ment with CPD, having had negative slides on days 7 and
14. Two patients developed severe anaemia within a week
of treatment with CPD and required admission to hospi-
tal for blood transfusion. The first was a 30-year male,
recruited with a Hb of 8.9, who complained of dizziness
but no fever on day-7 and had a Hb of 4.8 g/dl and a neg-
ative malaria slide. The second, an 11 year boy, was
recruited with a Hb of 11.6 g/dl (PCV 34%), but admitted
to hospital on day-3 with vomiting, a PCV of 21% and a
negative malaria slide. By day-4 the PCV had fallen to
13% (malaria slide still negative) necessitating a blood
transfusion. Neither patient became jaundiced, clinically
or biochemically, or had a palpable spleen. Three patients
taking SP aged 2, 4 and 15 years had SAEs, being admitted
to hospital on days 1, 2 and 10 respectively with fever and
found to have positive malaria blood slides. All three were
diagnosed with severe malaria and received parenteral
quinine before discharge. The 2 year old child required
blood transfusion due to a fall in their PCV from 27% to
13% by day-2.
Adherence with AL and CPD treatment regimes
Dosing questionnaire
This was completed by 371/442 (88%) participants who
took CPD and 185/209 (88.5%) who took AL. Missing
data was due to patient withdrawals from the study or loss
to follow up. All 185 participants in the AL group who
completed questionnaires said that they had taken all six
of their prescribed doses. Only three (0.8%) CPD partici-
pants admitted missing any doses.
MEMS™ results
Data were available for 181 patients in the CPD arm; 164
(90.6%) took all their doses out of the MEMS™ container
while 17 (9.4%) did not. Participants who took all their
doses were more likely to have an ACPR on day-28, p =
0.024 (Fishers exact). MEMS™ data were available for 87
AL treated patients; 80 (92%) took all their doses out of
the MEMS™ container and seven (8%) did not. None had
treatment failure by day-28 and so the association
between the MEMS™ data and day-28 outcome could not
be tested.
Table 2: Baseline characteristics by treatment group
Variable Statistic Treatment Group
CPD AL SP
Number of patients 422 209 210
Age (Years) Median 10.3 8.9 10.6
IQR 18.1 15.7 17.8
<5 years 129 57 53
Sex Female (%) 193(45.7) 89 (42.6) 82 (39.1)
Weight (kg) Median 27 24 27.5
IQR 38 36 38
Temperature (°C) Mean 37.6 37.8 37.5
S.D. 1.4 1.5 1.4
> 37.5°C Number 203 115 89
Parasite count (/μl) Mean 16263 21262 13489
Range 13  207000 20  258750 23  227500
Haemoglobin (g/dl) Mean 11.3 11.1 11.6
s.d 2.1 2.1 2.3
Missing 18 6 5
IQR = Inter-quartile range
S.D. = Standard DeviationPage 5 of 11
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Day-7 PK samples were analysed from 348/422 (82.5%)
of the CPD patients. Missing data were due to patient
withdrawals before day-7 and samples not collected or
lost. The DDS concentration in their day-7 sample was <
LLOQ of the assay in 174 (50%) of the participants. Par-
ticipants whose day-7 DDS concentration was < LLOQ
were younger, shorter in height and received a lower dap-
sone dose per kg body weight (p ≤ 0.001 for all) and were
less likely to have an ACPR outcome on day-28 than those
≥ LLOQ (104/178 (59.8%) vs. 143/174 (82.2%), p <
0.0001). For the 174 (50%) participants with quantifiable
Study profile (FU = Follow up)Figure 1
Study profile (FU = Follow up).
                    
841 Randomised
422 CPD group 209 AL group 210 SP group
4 lost to FU 
2 withdrawn 
213 day-42 FU
not planned 
137 Assessed for day-42 
efficacy outcome 
17 lost to FU 
25 withdrawn 
181 Assessed for day-28
efficacy outcome 
168 Assessed for day-28 
efficacy outcome 
33 lost to FU 
33 withdrawn 
2 lost to FU 
114 day-42 FU
not planned 
3 lost to FU 
3 withdrawn 
99 day-42 FU 
not planned 
17 lost to FU 
11 withdrawn 
65 Assessed for day-42 
efficacy outcome 
63 Assessed for day-42 
efficacy outcome 
6695 Did not meet 
inclusion criteria  
7536 Screened
356 Assessed for day-28 
efficacy outcome Page 6 of 11
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were higher in the ACPR group than the treatment failure
group, 248.3 ng/ml vs. 152.3 ng/ml respectively, p =
0.012 (Mann-Whitney). There was no difference in the
median day-7 DDS concentration between participants
who took all their CPD doses and those who did not
according to the MEMS™.
Day-7 lumefantrine concentration
Day-7 samples was analysed for LU in 167/209 (79.9%)
AL patients. Only 4/167 (2.4%) participants had day-7 LU
concentrations < LLOQ of the assay. The median (IQR)
LU concentrations for the 163 participants with quantifi-
able LU concentrations were 214 ng/ml (118321). The
small numbers of treatment failures or patients with sam-
ples < LLOQ does not permit meaningful comparisons of
lumefantrine levels in these groups. The median (IQR)
day-7 LU concentration in the 61 patients who took all
their doses out of the MEMS™ container was 193.0 ng/ml
(105.0  273.0), compared to 127.0 ng/ml (42.0  390.0) in
the five who did not, (p = 0.264, Mann-Whitney).
A previous study from Thailand reported that patients
with LU levels <175 ng/ml on day-7 are more likely to
experience recrudescence by day-42 [5]. In this study, of
the 58 participants in the AL group with day-42 efficacy
data, 16 (27.6%) had day-7 LU levels below this thresh-
old. Only one of these patients went on to have treatment
failure by day-42.
Discussion
Adherence to therapy is one of the cornerstones of suc-
cessful treatment and the more complex a treatment
regime is, the more likely it is that patients will fail to
adhere properly. Single dose therapy  SP is the only exam-
ple  is ideal, but widespread resistance means that SP is no
longer a useful option for control programmes. All of the
current treatment regimes promoted by the WHO are
multi-dose and there is no single dose therapy on the
horizon. The impact of poor adherence on treatment
effectiveness is difficult to measure but is an important
consideration for health policy makers. Methods for
measuring adherence to therapy including drug question-
naires, pill counting, assessment of pharmacy repeated
prescriptions, MEMS™ and drug level monitoring. None
of these is perfect, and measurement of adherence may
itself lead to a change in adherence behaviour of the indi-
vidual being monitored [6].
Table 3: Summary of the Day-28 ACPR rates and difference (95% confidence intervals), the data is not PCR corrected.
Day-28 Outcome ACPR Rate ACPR Difference (95% Confidence Intervals) P value
ITT (missing = failure)
CPD (n = 422) 63.7%
AL (n = 209) 85.2%
SP (n = 210) 50.0%
CPD vs SP 13.7%
(5.6%, 21.9%)
0.001
AL vs CPD 21.4%
(14.8%, 28.1%)
< 0.001
AL vs SP 35.2%
(26.9%, 43.5%)
< 0.001
ITT (missing = success)
CPD (n = 422) 79.4%
AL (n = 209) 98.6%
SP (n = 210) 70.5%
CPD vs SP 9.4%
(2.1%, 16.7%)
0.01
AL vs CPD 19.2%
(15.0%, 23.4%)
< 0.001
AL vs SP 28.6%
(22.2%, 35.0%)
< 0.001
Per Protocol
CPD (n = 356) 75.6%
AL (n = 181) 98.3%
SP (n = 168) 62.5%
CPD vs SP 13.1%
(4.5%, 21.6%)
0.003
AL vs CPD 22.8%
(17.9%, 27.6%)
< 0.001
AL vs SP 35.8%
(28.3%, 43.4%)
< 0.001Page 7 of 11
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combination therapy (ACT) in the world. By the end of
2008, it had been adopted as first line treatment policy for
uncomplicated malaria in 23 countries in Africa [7]. Treat-
ment with AL requires two doses daily for three consecu-
tive days, and CPD requires a single dose daily for three
consecutive days. In this study, two methods to measure
patient adherence to AL and CPD treatment, a dosing
questionnaire and MEMS™. The simplest of these meas-
ures, the drug questionnaire, is the one most open to
patient bias. The reported 100% adherence with AL and
99.2% adherence with CPD disagreed with the MEMS™
adherence data from the same patients. This discrepancy
between self-reported adherence and electronically meas-
ured adherence has been previously described, suggesting
that this method is an inaccurate way of assessing adher-
ence [8]. Patients may be keen to appear to be adherent
and so unwilling to report missed doses. A similar pattern
Table 4: Summary of the Day-42 ACPR rates and difference (95% confidence intervals), the data is not PCR corrected
Day-42 Outcome ACPR Rate ACPR Difference (95% Confidence Intervals) P value
ITT (missing = failure)
CPD (n = 166) 55.4%
AL (n = 82) 75.6%
SP (n = 82) 46.3%
CPD vs SP 9.1%
(-4.1%, 22.3%)
0.224
AL vs CPD 20.2%
(8.2%, 32.2%)
0.002
AL vs SP 29.3%
(15.0%, 43.5%)
< 0.001
ITT (missing = success)
CPD (n = 166) 72.9%
AL (n = 82) 96.3%
SP (n = 82) 69.5%
CPD vs SP 3.4%
(-8.7%, 15.4%)
0.653
AL vs CPD 23.4%
(15.6%, 31.3%)
< 0.001
AL vs SP 26.8%
(16.1%, 37.6%)
< 0.001
Per Protocol
CPD (n = 137) 75.6%
AL (n = 65) 98.3%
SP (n = 63) 62.5%
CPD vs SP 6.8%
(-7.6%, 21.3%)
0.425
AL vs CPD 28.2%
(18.9%, 37.6%)
< 0.001
AL vs SP 35.1%
(22.0%, 48.2%%)
< 0.001
Table 5: Mean changes in Haemoglobin [Hb] after treatment with CPD and AL compared to the Hb changes in the SP treatment 
group on days 7, 14 and 28.
Treatment Group Mean Hb
(g/dl)
Contrast with SP group
Mean Difference 95% confidence interval P-value
CPD
Day Number Day-7 10.42 -0.32 -0.57, -0.08 0.01
Day-14 10.83 -0.03 -0.47, 0.41 0.9
Day-28 11.29 0.12 -0.18, 0.42 0.45
AL
Day Number Day-7 11.05 0.32 0.04, 0.60 0.03
Day-14 11.31 0.44 -0.06, 0.94 0.09
Day-28 11.81 0.64 0.30, 0.98 < 0.001Page 8 of 11
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(ART) using questionnaires has been noted previously in
HIV positive patients in Malawi [9].
MEMS™ provide a more objective assessment of adher-
ence, although the interpretation of their results can be
difficult. They have been used extensively to monitor
patients on long-term treatment such as anti-retroviral
therapy. MEMS™ record the date and time at each opening
of the pill bottle. The numbers of tablets removed each
time or whether the tablets are actually taken cannot be
recorded. Patients taking AL may open the bottle once in
the morning and remove all the tablets required for both
the morning and evening doses at that time and this
would be interpreted as poor adherence due to the missed
evening dose. Patients are also known to "play" with their
pill bottles and, as a result, multiple openings are
recorded each day when no drug has actually been taken.
In this study, over 90% of the patients receiving CPD took
all their doses out of the MEMS™ container and these
patients were more likely to have an ACPR on day-28 than
those participants who did not, p = 0.024. For AL, the
MEMS™ data suggested that 92% of the patients took all
of their six doses. There were only three treatment failures
in the AL treatment group by day-28 making it impossible
to examine the association between the MEMS™ results
and treatment response.
The median day-7 LU concentration reported here was
214 ng/ml, after a mean total LU dose of 63.9 mg/kg. This
is lower than the median of 528 ng/ml reported by Price
et al after a mean total dose of 61.2 mg/kg of LU [5]. This
variability in LU concentration may reflect a number of
factors including whether the tablets were taken with fatty
foods (to improve LU absorption), and differences in the
disposition of the drug between individuals of different
age, sex, weights and other factors. This study was not
powered or designed to investigate all of these possible
causes of variability. Differences in patient adherence
(number of tablets taken) may explain some of the differ-
ences between these studies. In this study only the first
dose of AL was supervised, while in the Price study all
doses were supervised. However in this study, only five
patients in the AL group took less than their full treatment
course according to the MEMS™ and there was no statisti-
cal difference between the LU concentrations in these
patients compared to those who took all their tablets.
Other studies have addressed adherence with AL. In Bang-
ladesh, an adherence rate of 93% was reported using pill
counting and questionnaires and there was no difference
noted in day-7 LU concentrations in poorly adherent
patients [10]. Average adherence rates of 94% to AL have
been reported from a series of home treatment studies in
children from Uganda and Ghana [11]. In these studies,
adherence was assessed using interviews with the parents
of the children. Finally, a study from Uganda reported
adherence levels of 90% using pill counting and question-
naires and mean day-3 LU concentrations were lower in
non-adherent than adherent patients [12].
The measurement of the day-7 drug concentration has
been proposed as a way to predict treatment outcome in
malaria treatment studies [13]. A study from Thailand
using AL for uncomplicated malaria demonstrated that
patients with plasma LU levels below 175 ng/ml on day-7
were more likely to experience recrudescence by day-42
[5]. However, this cut-off was not associated with day-42
treatment failure in this study; 16 (27.6%) patients had
concentrations below this threshold and only one of these
had a treatment failure and illustrating that drug concen-
tration thresholds, predictive of treatment response in SE
Asia, may not be appropriate for use in Africa.
Malawi was the first country in Africa to introduce SP as
its first line treatment for uncomplicated malaria in 1993.
In 2007, it was withdrawn by the national Malaria Con-
trol Programme, and replaced by AL. The results reported
here confirm that SP was insufficiently effective for a first-
line malaria treatment in Malawi at the time of this study;
the day-28 ACPR rate for SP of 62.5% by PP analysis. In
contrast, the PP day-28 and day-42 ACPR rates for AL were
98.3% and 95.4% respectively, in keeping with rates
reported from other countries in the region including
Mali, Ghana and Uganda, whether AL is taken supervised
in an efficacy trial or unsupervised [14-16]. These results
show that treatment appears to be successful even in the
few patients who did not take all their tablets out of their
MEMS™ container, suggesting that AL was "forgiving", still
having a therapeutic effect in individuals who have
missed doses [17].
The PP day-28 ACPR rate with CPD was 75.6% and was
lower than had been expected. A longitudinal study from
Malawi in 1999 reported a day-14 efficacy of around 96%
[1]. Some of this difference may be due to poor adher-
ence; the MEMS™ data showed that 9.4% of the patients
did not take the full course of CPD and that these patients
were more likely to fail treatment. PCR correction for rein-
fection would also have increased this ACPR rate; no
attempt was made to distinguish reinfections from recru-
descent malaria, because from a programmatic viewpoint,
both of these are important components of the malaria
burden in a population. The poor CPD efficacy might also
have been due to increased parasite resistance.
There were no SAEs in the AL treatment group, consistent
with data from other studies reporting that this combina-
tion therapy is well-tolerated and highly efficacious. ThreePage 9 of 11
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Malaria Journal 2009, 8:204 http://www.malariajournal.com/content/8/1/204patients in the SP group required hospital admission with
features of severe malaria within 10 days of recruitment to
the study, probably reflecting the poor efficacy of SP. One
child died having developed features of severe malaria a
day after recruitment and treatment with CPD; it is impos-
sible to know whether this resulted from poor treatment
efficacy or was an inevitable consequence of that child's
infection. The production of CPD was halted and the drug
withdrawn because of concern about haemolysis. Two
patients developed severe anaemia within a week of treat-
ment with CPD. In both, the Hb fell by around 50%
despite parasite clearance, making it unlikely that malaria
was responsible. Dapsone-induced haemolysis is more
common in G6PD deficient individuals but the G6PD sta-
tus of participants in this study is unknown.
Conclusion
SP has failed in Malawi and should no longer be used as a
treatment for uncomplicated malaria. Its continued role
in intermittent presumptive therapy in pregnancy pro-
grammes needs to be evaluated. In this study, AL was
highly effective, even with unsupervised dosing and was
well tolerated. Adherence to the six-dose regime was good
and treatment was effective, even in those who did not
properly comply with the dosing schedule. Self-reported
adherence appears to be an unreliable measure of adher-
ence in this population and may lead to over-estimation
of the true level of adherence. This study provides strong
reassurance of the effectiveness of AL as it is rolled out
across sub-Saharan Africa.
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